Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / SPONSORED ADS
-
Total 13F shares
-
54,623,068
-
Share change
-
+8,334,828
-
Total reported value
-
$548,412,337
-
Put/Call ratio
-
250%
-
Price per share
-
$10.04
-
Number of holders
-
61
-
Value change
-
+$114,858,185
-
Number of buys
-
43
-
Number of sells
-
17
Institutional Holders of GRACELL BIOTECHNOLOGIES INC - SPONSORED ADS (GRCL) as of Q4 2023
As of 31 Dec 2023,
GRACELL BIOTECHNOLOGIES INC - SPONSORED ADS (GRCL) was held by
61 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
54,623,068 shares.
The largest 10 holders included
Temasek Holdings (Private) Ltd, Vivo Capital, LLC, ORBIMED ADVISORS LLC, Sio Capital Management, LLC, TCG Crossover Management, LLC, TANG CAPITAL MANAGEMENT LLC, BAKER BROS. ADVISORS LP, Pentwater Capital Management LP, Pivotal bioVenture Partners Investment Advisor LLC, and ADAGE CAPITAL PARTNERS GP, L.L.C..
This page lists
61
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.